Ensuring Medicine Supply Chain Resilience in Disasters: A Grounded Approach

By Staff Writer

August 18, 2023

Medicines and medical supplies are crucial in maintaining human health, particularly during disasters when their availability can be significantly impacted. This is especially true in developing countries, where the provision of these supplies is a critical priority. Disruptions in the medication supply chain can lead to serious consequences, from loss of revenue for companies to endangering lives. This article explores the causes, strategies, and consequences of such disruptions, using the Kermanshah, Iran earthquake in 2018 as a case study.

The study found that “waste of time and resources” was the most critical issue in the medication supply chain during disasters. Strategies to reduce this waste, such as efficient resource management and the use of an up-to-date information system, were identified as crucial in increasing supply chain resilience. Sociocultural factors, as well as the need for planning and designing an appropriate disaster management structure, were also highlighted as significant underlying factors affecting the prevention of resource waste.

The study emphasised the need for effective disaster management planning, and the importance of a comprehensive needs assessment based on the region’s characteristics, including its epidemiological needs, disease, and demographic characteristics. Paying attention to sociocultural factors and developing localised policies under cultural conditions, social needs, and the level of acceptance and cooperation of the people of each region were also recommended.


To achieve resilience in the medication supply chain during disasters, health policymakers must seek applied and context-based strategies for decreasing the waste of resources. These strategies should include sociocultural interventions, preparing necessary information infrastructures, and improving coordination among the stewards and the community during disasters. Improving logistic operations and monitoring the coordination between the local need assessments and the pharmaceutical supplies and procurement are also essential steps in improving medication supply chain resilience. 

Reference url

Recent Posts

Novo Nordisk performance
      

Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share

🚀 Understand the market dynamics of Novo Nordisk’s GLP-1 Market Share Decline.

A case of demand underestimation, supply chain strain, and competitor agility. Using systems thinking, we unpack the dynamic forces behind Eli Lilly’s surge—and what strategic levers pharma leaders must pull to stay ahead.

#SyenzaNews #PharmaStrategy #MarketDynamics #NovoNordisk #EliLilly #GLP1

Tolebrutinib MS analysis
          

Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS

💡 Can tolebrutinib reshape the treatment landscape for progressive multiple sclerosis?

A recent report from the Institute for Clinical and Economic Review reveals promising insights on tolebrutinib, demonstrating a 31% reduction in disability progression for patients with non-relapsing secondary progressive MS. Yet, mixed outcomes and potential safety concerns raise critical questions about its long-term efficacy and market access.

Explore the nuances of this groundbreaking therapy and its implications for healthcare economics.

#SyenzaNews #HealthEconomics #MarketAccess

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.